HIRA: A Potential Drug Target and Biomarker for Diseases (G7290)

Target Name: HIRA

NCBI ID: G7290

HIRA

HIRA: A Potential Drug Target and Biomarker for Diseases

Human investigated gene (HIRA) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. HIRA is a gene that is expressed in many different tissues and cells in the body, including the brain, heart, kidneys, and liver. It is a member of the HIR family of genes, which are characterized by the presence of a specific intron in the first exon that is usually excluded in computable alignments.

Disease association

HIRA has been associated with a number of diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that HIRA is frequently expressed in various types of cancer, including breast, ovarian, and prostate cancer. HIRA has also been implicated in a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In addition, HIRA has been associated with a number of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis.

Potential drug targets

HIRA is a potential drug target due to its involvement in a number of diseases and conditions. One potential mechanism by which HIRA could be targeted is through its role in cell signaling. HIRA has been shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of tissues and organs, and is a target for a number of drugs that are used to treat cancer and other diseases.

Another potential mechanism by which HIRA could be targeted is through its role in the regulation of gene expression. HIRA has been shown to play a role in the regulation of gene expression in a variety of tissues and cells, including the brain. This suggests that HIRA could be a potential drug target for a number of neurodegenerative diseases.

Biomarker potential

HIRA has also been shown to be a potential biomarker for a number of diseases. For example, studies have shown that HIRA is expressed in the brains of individuals with Alzheimer's disease, and that it is associated with the development of this disease. In addition, HIRA has been shown to be expressed in the blood vessels of individuals with neurodegenerative diseases, and that it may be a potential biomarker for these conditions.

Conclusion

HIRA is a gene that has been associated with a number of diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. As a potential drug target and biomarker, HIRA is a promising target for future research and clinical development. Further studies are needed to fully understand the role of HIRA in these diseases and to determine its potential as a drug or biomarker.

Protein Name: Histone Cell Cycle Regulator

Functions: Cooperates with ASF1A to promote replication-independent chromatin assembly. Required for the periodic repression of histone gene transcription during the cell cycle. Required for the formation of senescence-associated heterochromatin foci (SAHF) and efficient senescence-associated cell cycle exit

The "HIRA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIRA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets